RELYVRIO

This brand name is authorized in United States.

Active ingredients

The drug RELYVRIO contains a combination of these active pharmaceutical ingredients (APIs):

`1`	Sodium phenylbutyrate UNII `NT6K61736T` - SODIUM PHENYLBUTYRATE
	Sodium phenylbutyrate is a pro-drug and is rapidly metabolised to phenylacetate. Phenylacetate is a metabolically active compound that conjugates with glutamine via acetylation to form phenylacetylglutamine which is then excreted by the kidneys. On a molar basis, phenylacetylglutamine is comparable to urea (each containing 2 moles of nitrogen) and therefore provides an alternate vehicle for waste nitrogen excretion.
	Read more about Sodium phenylbutyrate
`2`	Ursodoxicoltaurine UNII `60EUX8MN5X` - TAURURSODIOL
	Read more about Ursodoxicoltaurine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RELYVRIO Powder for oral suspension	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	73063-035

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.